Alexander Lesokhin, MD talks about newly diagnosed multiple myeloma patients

The potential role of belantamab mafodotin in multiple myelomaПодробнее

Dr. Lesokhin Discusses Exciting Advances in Multiple MyelomaПодробнее

KRd vs VRd as Induction Therapy in Newly Diagnosed High-Risk Multiple MyelomaПодробнее

Can diet impact treatment outcomes and progression of patients with multiple myeloma?Подробнее

Evaluating the safety and efficacy of elranatamab in multiple myelomaПодробнее

Initial Safety Results for Phase 2 MagnetisMM-3 Trial Presented at ASCO 2022Подробнее

SC vs. IV administration of a BCMA-CD3 bispecific antibody for R/R myelomaПодробнее

Alexander Lesokhin, MD provides an update on the CASTOR trial presented at ASCO 2016Подробнее

Alexander Lesokhin, MD explains therapy combinations for newly diagnosed multiple myeloma patientsПодробнее

Alexander Lesokhin, MD talks about the pros/cons of an all-oral regimen in the treatment of MMПодробнее

Alexander Lesokhin, MD discusses the development of immunotherapies for multiple myeloma patientsПодробнее

Alexander Lesokhin, MD on sequencing therapies in relapsed multiple myeloma patientsПодробнее

Alexander Lesokhin, MD on the use of daratumumab to treat multiple myeloma patientsПодробнее